<?xml version="1.0" encoding="utf-8"?>
<Label drug="NitroMist" setid="1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6">
<Text><Section name="DOSAGE &amp; ADMINISTRATION SECTION" id="34068-7">
2 DOSAGE AND ADMINISTRATION

 At the onset of an attack, one metered spray or two metered sprays should be administered on or under the tongue. A spray may be repeated approximately every 5 minutes as needed ( 2 ). 
 Maximum of 3 metered sprays are recommended within a 15-minute period. If chest pain persists after a total of 3 sprays, prompt medical attention is recommended ( 2 ). 
 May be used prophylactically 5 minutes to 10 minutes before engaging in activities that might precipitate an acute attack ( 2 ). 

2.1 Recommended Dosage

 At the onset of an attack, one metered spray or two metered sprays should be administered on or under the tongue. A spray may be repeated approximately every 5 minutes as needed. If two sprays are used initially, the patient may only administer one more spray after waiting 5 minutes. No more than 3 metered sprays are recommended within a 15-minute period. If chest pain persists after a total of 3 sprays, prompt medical attention is recommended. NitroMist may be used prophylactically 5 minutes to 10 minutes before engaging in activities that might precipitate an acute attack. 

2.2 Priming the Container

 After an initial priming of 10 sprays, each metered spray of NitroMist delivers 33 mg of solution containing 400 mcg of nitroglycerin. It will remain adequately primed for 6 weeks. If the product is not used within 6 weeks, it can be adequately re-primed with 2 sprays. NitroMist is available in either 230 metered sprays or 90 metered sprays per container, but the total number of available doses depends on the number of sprays per use (1 spray or 2 sprays), and the frequency of priming. 

2.3 Administration

 During use the patient should rest, ideally in the sitting position. The container should be held vertically with the valve head uppermost and the spray orifice as close to the mouth as possible. The dose should preferably be sprayed into the mouth on or under the tongue by pressing the button firmly and the mouth should be closed immediately after each dose. THE SPRAY SHOULD NOT BE INHALED. Patients should be instructed to familiarize themselves with the position of the spray orifice, which can be identified by the finger rest on top of the valve, in order to facilitate orientation for administration at night. 

 Do not shake container. 
 Remove plastic cap. 
 If this is the first time using the bottle, press actuator button 10 times to ensure proper dose priming (holding unit away from yourself and others). 
 Hold container upright with forefinger on top of the actuator button. 
 Open mouth and bring the container as close as possible. 
 Press the actuator button firmly with forefinger to release spray(s) onto or under the tongue. 
 Release button and close mouth. The medication should not be spit out or the mouth rinsed for 5 minutes to 10 minutes following administration. 
 If a second administration is required to obtain relief, repeat steps 4, 5, and 6. No more than 3 metered sprays can be given within a 15-minute period. 
 Replace plastic cover. 
 If the product is not used for more than 6 weeks, then it can be adequately re-primed with 2 sprays. 

 The level of the liquid in the container should be periodically checked. While the container is in the upright position, if the liquid reaches the top or middle of the hole on the side of the container, one should order more. When the liquid reaches the bottom of the hole, the remaining doses will have less than label content.</Section>
<Section name="CONTRAINDICATIONS SECTION" id="34070-3">
4 CONTRAINDICATIONS

 Use of a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5 inhibitors), such as sildenafil, vardenafil, and tadalafil ( 4.1 ) 
 Severe anemia ( 4.2 ) 
 Increased intracranial pressure ( 4.3 ) 
 History of hypersensitivity to NitroMist or to other nitrates or nitrites ( 4.4 ) 

4.1 PDE5 Inhibitor Use

 Administration of NitroMist is contraindicated in patients who are using a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), as PDE5 inhibitors such as sildenafil, vardenafil, and tadalafil have been shown to potentiate the hypotensive effects of organic nitrates [see 
 DRUG INTERACTIONS ( 7.1 ) ]. 

4.2 Severe Anemia

 NitroMist is contraindicated in patients with severe anemia. 

4.3 Increased Intracranial Pressure

 NitroMist is contraindicated in patients with increased intracranial pressure. 

4.4 Hypersensitivity

 NitroMist is contraindicated in patients who have shown hypersensitivity to it or to other nitrates or nitrites. Skin reactions consistent with hypersensitivity have been observed with organic nitrates.</Section>
<Section name="WARNINGS AND PRECAUTIONS SECTION" id="43685-7">
5 WARNINGS AND PRECAUTIONS

 Tolerance: Excessive use may lead to tolerance ( 5.1 ). 

5.1 Tolerance

 Excessive use may lead to the development of tolerance. Only the smallest number of doses required for effective relief of the acute anginal attack should be used [see 
 DOSAGE AND ADMINISTRATION ( 2 ) ]. 
 As tolerance to other forms of nitroglycerin develops, the effect of sublingual nitroglycerin on exercise tolerance, although still observable, is reduced. 

5.2 Hypotension

 Severe hypotension, particularly with upright posture, may occur even with small doses of nitroglycerin. The drug should therefore be used with caution in patients who may be volume-depleted or who, for whatever reason, are already hypotensive. Hypotension induced by nitroglycerin may be accompanied by paradoxical bradycardia and increased angina pectoris. 
 The benefits of NitroMist in patients with acute myocardial infarction or congestive heart failure have not been established. If one elects to use NitroMist in these conditions, careful clinical or hemodynamic monitoring must be used because of the possibility of hypotension and tachycardia. 

5.3 Hypertrophic Cardiomyopathy

 Nitrate therapy may aggravate the angina caused by hypertrophic cardiomyopathy. 

5.4 Headache

 Nitroglycerin produces dose-related headaches, which may be severe. Tolerance to headaches occurs.</Section>
<Section name="DRUG INTERACTIONS SECTION" id="34073-7">
7 DRUG INTERACTIONS

 PDE5 inhibitors: Concomitant use contraindicated ( 4.1 , 7.1 ) 
 Antihypertensives: Possible additive hypotensive effects ( 7.2 ) 
 Aspirin: increased nitroglycerin levels ( 7.3 ) 
 Tissue-type plasminogen activator (t-PA): decreased thrombolytic effect ( 7.4 ) 
 Heparin: anticoagulant effect of heparin may be reduced. Monitor APTT. ( 7.5 ) 
 Ergotamine: increased bioavailability of ergotamine. Avoid concomitant use. ( 7.6 ) 

7.1 PDE5 Inhibitors

 Administration of NitroMist is contraindicated in patients who are using a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). PDE5 inhibitors such as sildenafil, vardenafil, and tadalafil have been shown to potentiate the hypotensive effects of organic nitrates. 
 The time course and dose dependence of this interaction have not been studied, and use within a few days of one another cannot be recommended. Appropriate supportive care for the severe hypotension has not been studied, but it seems reasonable to treat this as a nitrate overdose, with elevation of the extremities and with central volume expansion. The use of any form of nitroglycerin during the early days of acute myocardial infarction requires particular attention to hemodynamic monitoring and clinical status. 

7.2 Antihypertensives

 Patients receiving antihypertensive drugs, beta-adrenergic blockers, and nitrates should be observed for possible additive hypotensive effects. Marked orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used concomitantly. 
 Labetolol blunts the reflex tachycardia produced by nitroglycerin without preventing its hypotensive effects. If labetolol is used with nitroglycerin in patients with angina pectoris, additional hypotensive effects may occur. 

7.3 Aspirin

 Coadministration of aspirin and nitroglycerin has been reported to result in increased nitroglycerin maximum concentrations by as much as 67% and AUC by 73% when administered as a single dose. The vasodilatory and hemodynamic effects of nitroglycerin may be enhanced by concomitant administration of aspirin. 

7.4 Tissue-type Plasminogen Activator (t-PA)

 Intravenous administration of nitroglycerin decreases the thrombolytic effect of tissue-type plasminogen activator (t-PA). Plasma levels of t-PA are reduced when coadministered with nitroglycerin. Therefore, caution should be observed in patients receiving nitroglycerin during t-PA therapy. 

7.5 Heparin

 Intravenous nitroglycerin reduces the anticoagulant effect of heparin. Activated partial thromboplastin times (APTT) should be monitored in patients receiving heparin and intravenous nitroglycerin. It is not known if this effect occurs following single nitroglycerin doses. 

7.6 Ergotamine

 Oral administration of nitroglycerin markedly decreases the first-pass metabolism of dihydroergotamine and subsequently increases its oral bioavailability. Ergotamine is known to precipitate angina pectoris. Therefore, patients receiving sublingual nitroglycerin should avoid ergotamine and related drugs or be monitored for symptoms of ergotism if this is not possible.</Section>
</Text><Sentences>
<Sentence id="67" LabelDrug="NitroMist" section="34068-7">
<SentenceText>After an initial priming of 10 sprays , each metered spray of NitroMist delivers 33 mg of solution containing 400 mcg of nitroglycerin .</SentenceText>
</Sentence>
<Sentence id="68" LabelDrug="NitroMist" section="34070-3">
<SentenceText>Administration of NitroMist is contraindicated in patients who are using a selective inhibitor of cyclic guanosine monophosphate ( cGMP ) - specific phosphodiesterase type 5 ( PDE5 ) , as PDE5 inhibitors such as sildenafil , vardenafil , and tadalafil have been shown to potentiate the hypotensive effects of organic nitrates see DRUG INTERACTIONS ( 7.1 ) .</SentenceText>
<Mention id="M10" type="Trigger" span="271 10" str="potentiate"/>
<Mention id="M2" type="Precipitant" span="188 15" str="PDE5 inhibitors" code="N0000175599"/>
<Mention id="M12" type="SpecificInteraction" span="286 19" str="hypotensive effects" code="45007003: Low blood pressure (disorder)"/>
<Mention id="M5" type="Precipitant" span="212 10" str="sildenafil" code="N0000022115"/>
<Mention id="M8" type="Precipitant" span="242 9" str="tadalafil" code="N0000010536"/>
<Mention id="M11" type="Precipitant" span="225 10" str="vardenafil" code="N0000148820"/>
<Interaction id="I1" type="Pharmacodynamic interaction" trigger="M10" precipitant="M2" effect="M12"/>
<Interaction id="I2" type="Pharmacodynamic interaction" trigger="M10" precipitant="M5" effect="M12"/>
<Interaction id="I3" type="Pharmacodynamic interaction" trigger="M10" precipitant="M8" effect="M12"/>
<Interaction id="I4" type="Pharmacodynamic interaction" trigger="M10" precipitant="M11" effect="M12"/>
</Sentence>
<Sentence id="68" LabelDrug="NitroMist" section="34070-3">
<SentenceText>Administration of NitroMist is contraindicated in patients who are using a selective inhibitor of cyclic guanosine monophosphate ( cGMP ) - specific phosphodiesterase type 5 ( PDE5 ) , as PDE5 inhibitors such as sildenafil , vardenafil , and tadalafil have been shown to potentiate the hypotensive effects of organic nitrates see DRUG INTERACTIONS ( 7.1 ) .</SentenceText>
<Mention id="M22" type="Trigger" span="271 10" str="potentiate"/>
<Mention id="M14" type="Precipitant" span="188 15" str="PDE5 inhibitors" code="N0000175599"/>
<Mention id="M24" type="SpecificInteraction" span="286 19" str="hypotensive effects" code="45007003: Low blood pressure (disorder)"/>
<Mention id="M17" type="Precipitant" span="212 10" str="sildenafil" code="N0000022115"/>
<Mention id="M20" type="Precipitant" span="242 9" str="tadalafil" code="N0000010536"/>
<Mention id="M23" type="Precipitant" span="225 10" str="vardenafil" code="N0000148820"/>
<Interaction id="I5" type="Pharmacodynamic interaction" trigger="M22" precipitant="M14" effect="M24"/>
<Interaction id="I6" type="Pharmacodynamic interaction" trigger="M22" precipitant="M17" effect="M24"/>
<Interaction id="I7" type="Pharmacodynamic interaction" trigger="M22" precipitant="M20" effect="M24"/>
<Interaction id="I8" type="Pharmacodynamic interaction" trigger="M22" precipitant="M23" effect="M24"/>
</Sentence>
<Sentence id="68" LabelDrug="NitroMist" section="34070-3">
<SentenceText>Administration of NitroMist is contraindicated in patients who are using a selective inhibitor of cyclic guanosine monophosphate ( cGMP ) - specific phosphodiesterase type 5 ( PDE5 ) , as PDE5 inhibitors such as sildenafil , vardenafil , and tadalafil have been shown to potentiate the hypotensive effects of organic nitrates see DRUG INTERACTIONS ( 7.1 ) .</SentenceText>
<Mention id="M34" type="Trigger" span="271 10" str="potentiate"/>
<Mention id="M26" type="Precipitant" span="188 15" str="PDE5 inhibitors" code="N0000175599"/>
<Mention id="M36" type="SpecificInteraction" span="286 19" str="hypotensive effects" code="45007003: Low blood pressure (disorder)"/>
<Mention id="M29" type="Precipitant" span="212 10" str="sildenafil" code="N0000022115"/>
<Mention id="M32" type="Precipitant" span="242 9" str="tadalafil" code="N0000010536"/>
<Mention id="M35" type="Precipitant" span="225 10" str="vardenafil" code="N0000148820"/>
<Interaction id="I9" type="Pharmacodynamic interaction" trigger="M34" precipitant="M26" effect="M36"/>
<Interaction id="I10" type="Pharmacodynamic interaction" trigger="M34" precipitant="M29" effect="M36"/>
<Interaction id="I11" type="Pharmacodynamic interaction" trigger="M34" precipitant="M32" effect="M36"/>
<Interaction id="I12" type="Pharmacodynamic interaction" trigger="M34" precipitant="M35" effect="M36"/>
</Sentence>
<Sentence id="68" LabelDrug="NitroMist" section="34070-3">
<SentenceText>Administration of NitroMist is contraindicated in patients who are using a selective inhibitor of cyclic guanosine monophosphate ( cGMP ) - specific phosphodiesterase type 5 ( PDE5 ) , as PDE5 inhibitors such as sildenafil , vardenafil , and tadalafil have been shown to potentiate the hypotensive effects of organic nitrates see DRUG INTERACTIONS ( 7.1 ) .</SentenceText>
<Mention id="M46" type="Trigger" span="271 10" str="potentiate"/>
<Mention id="M38" type="Precipitant" span="188 15" str="PDE5 inhibitors" code="N0000175599"/>
<Mention id="M48" type="SpecificInteraction" span="286 19" str="hypotensive effects" code="45007003: Low blood pressure (disorder)"/>
<Mention id="M41" type="Precipitant" span="212 10" str="sildenafil" code="N0000022115"/>
<Mention id="M44" type="Precipitant" span="242 9" str="tadalafil" code="N0000010536"/>
<Mention id="M47" type="Precipitant" span="225 10" str="vardenafil" code="N0000148820"/>
<Interaction id="I13" type="Pharmacodynamic interaction" trigger="M46" precipitant="M38" effect="M48"/>
<Interaction id="I14" type="Pharmacodynamic interaction" trigger="M46" precipitant="M41" effect="M48"/>
<Interaction id="I15" type="Pharmacodynamic interaction" trigger="M46" precipitant="M44" effect="M48"/>
<Interaction id="I16" type="Pharmacodynamic interaction" trigger="M46" precipitant="M47" effect="M48"/>
</Sentence>
<Sentence id="69" LabelDrug="NitroMist" section="34073-7">
<SentenceText>(7.5) Ergotamine: increased bioavailability of ergotamine.</SentenceText>
<Mention id="M49" type="Trigger" span="18 25" str="increased bioavailability"/>
<Mention id="M50" type="Precipitant" span="6 10" str="Ergotamine" code="N0000006354"/>
<Interaction id="I17" type="Pharmacokinetic interaction" trigger="M49" precipitant="M50" effect="C54357"/>
</Sentence>
<Sentence id="70" LabelDrug="NitroMist" section="34073-7">
<SentenceText>(7.6) Administration of NitroMist is contraindicated in patients who are using a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type5 (PDE5).</SentenceText>
<Mention id="M51" type="Trigger" span="37 15" str="contraindicated"/>
<Mention id="M52" type="Precipitant" span="81 100" str="selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type5 (PDE5)" code="NO MAP"/>
<Interaction id="I18" type="Unspecified interaction" trigger="M51" precipitant="M52"/>
</Sentence>
<Sentence id="71" LabelDrug="NitroMist" section="34073-7">
<SentenceText>Activated partial thromboplastin times ( APTT ) should be monitored in patients receiving heparin and intravenous nitroglycerin .</SentenceText>
<Mention id="M53" type="Trigger" span="48 19" str="should be monitored"/>
<Mention id="M54" type="Precipitant" span="90 7" str="heparin" code="N0000006341"/>
<Interaction id="I19" type="Unspecified interaction" trigger="M53" precipitant="M54"/>
</Sentence>
<Sentence id="72" LabelDrug="NitroMist" section="34073-7">
<SentenceText>Activated partial thromboplastin times (APTT) should be monitored in patients receiving heparin and intravenous nitroglycerin.</SentenceText>
<Mention id="M55" type="Trigger" span="46 19" str="should be monitored"/>
<Mention id="M56" type="Precipitant" span="88 7" str="heparin" code="N0000006341"/>
<Interaction id="I20" type="Unspecified interaction" trigger="M55" precipitant="M56"/>
</Sentence>
<Sentence id="73" LabelDrug="NitroMist" section="34073-7">
<SentenceText>Appropriate supportive care for the severe hypotension has not been studied, but it seems reasonable to treat this as a nitrate overdose, with elevation of the extremities and with central volume expansion.</SentenceText>
</Sentence>
<Sentence id="74" LabelDrug="NitroMist" section="34073-7">
<SentenceText>Aspirin : increased nitroglycerin levels ( 7.3 ) .</SentenceText>
<Mention id="M57" type="Trigger" span="10 9;34 6" str="increased | levels"/>
<Mention id="M58" type="Precipitant" span="0 7" str="Aspirin" code="N0000006582"/>
<Interaction id="I21" type="Pharmacokinetic interaction" trigger="M57" precipitant="M58" effect="C54355"/>
</Sentence>
<Sentence id="75" LabelDrug="NitroMist" section="34073-7">
<SentenceText>Coadministration of aspirin and nitroglycerin has been reported to result in increased nitroglycerin maximum concentrations by as much as 67 % and AUC by 73 % when administered as a single dose .</SentenceText>
<Mention id="M61" type="Trigger" span="77 9;109 14" str="increased | concentrations"/>
<Mention id="M62" type="Precipitant" span="20 7" str="aspirin" code="N0000006582"/>
<Interaction id="I22" type="Pharmacokinetic interaction" trigger="M61" precipitant="M62" effect="C54602"/>
<Interaction id="I23" type="Pharmacokinetic interaction" trigger="M61" precipitant="M62" effect="C54605"/>
</Sentence>
<Sentence id="75" LabelDrug="NitroMist" section="34073-7">
<SentenceText>Coadministration of aspirin and nitroglycerin has been reported to result in increased nitroglycerin maximum concentrations by as much as 67 % and AUC by 73 % when administered as a single dose .</SentenceText>
<Mention id="M65" type="Trigger" span="77 9;109 14" str="increased | concentrations"/>
<Mention id="M66" type="Precipitant" span="20 7" str="aspirin" code="N0000006582"/>
<Interaction id="I24" type="Pharmacokinetic interaction" trigger="M65" precipitant="M66" effect="C54602"/>
<Interaction id="I25" type="Pharmacokinetic interaction" trigger="M65" precipitant="M66" effect="C54605"/>
</Sentence>
<Sentence id="76" LabelDrug="NitroMist" section="34073-7">
<SentenceText>Ergotamine is known to precipitate angina pectoris.</SentenceText>
</Sentence>
<Sentence id="77" LabelDrug="NitroMist" section="34073-7">
<SentenceText>If labetolol is used with nitroglycerin in patients with angina pectoris , additional hypotensive effects may occur .</SentenceText>
<Mention id="M67" type="Trigger" span="75 10;106 9" str="additional | may occur"/>
<Mention id="M68" type="Precipitant" span="3 9" str="labetolol" code="N0000006446"/>
<Mention id="M69" type="SpecificInteraction" span="86 19" str="hypotensive effects" code="45007003: Low blood pressure (disorder)"/>
<Interaction id="I26" type="Pharmacodynamic interaction" trigger="M67" precipitant="M68" effect="M69"/>
</Sentence>
<Sentence id="78" LabelDrug="NitroMist" section="34073-7">
<SentenceText>Intravenous administration of nitroglycerin decreases the thrombolytic effect of tissue-type plasminogen activator ( t-PA ) .</SentenceText>
<Mention id="M70" type="Trigger" span="44 9;71 6" str="decreases | effect"/>
<Mention id="M71" type="Precipitant" span="81 42" str="tissue-type plasminogen activator ( t-PA )" code="N0000007047"/>
<Mention id="M72" type="SpecificInteraction" span="44 9;58 19" str="decreases | thrombolytic effect" code="NO MAP"/>
<Interaction id="I27" type="Pharmacodynamic interaction" trigger="M70" precipitant="M71" effect="M72"/>
</Sentence>
<Sentence id="79" LabelDrug="NitroMist" section="34073-7">
<SentenceText>Intravenous nitroglycerin reduces the anticoagulant effect of heparin .</SentenceText>
<Mention id="M73" type="Trigger" span="26 7" str="reduces"/>
<Mention id="M74" type="Precipitant" span="62 7" str="heparin" code="N0000006341"/>
<Mention id="M75" type="SpecificInteraction" span="26 32" str="reduces the anticoagulant effect" code="76612001:  Hypercoagulability state (finding)"/>
<Interaction id="I28" type="Pharmacodynamic interaction" trigger="M73" precipitant="M74" effect="M75"/>
</Sentence>
<Sentence id="80" LabelDrug="NitroMist" section="34073-7">
<SentenceText>It is not known if this effect occurs following single nitroglycerin doses.</SentenceText>
</Sentence>
<Sentence id="81" LabelDrug="NitroMist" section="34073-7">
<SentenceText>Labetolol blunts the reflex tachycardia produced by nitroglycerin without preventing its hypotensive effects .</SentenceText>
</Sentence>
<Sentence id="82" LabelDrug="NitroMist" section="34073-7">
<SentenceText>Marked orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used concomitantly.</SentenceText>
<Mention id="M78" type="SpecificInteraction" span="0 30" str="Marked orthostatic hypotension" code="28651003: Orthostatic hypotension (disorder)"/>
<Mention id="M77" type="Precipitant" span="54 24" str="calcium channel blockers" code="N0000029119"/>
<Interaction id="I29" type="Pharmacodynamic interaction" trigger="M78" precipitant="M77" effect="M78"/>
</Sentence>
<Sentence id="83" LabelDrug="NitroMist" section="34073-7">
<SentenceText>Oral administration of nitroglycerin markedly decreases the first-pass metabolism of dihydroergotamine and subsequently increases its oral bioavailability .</SentenceText>
<Mention id="M79" type="Trigger" span="46 9;71 10" str="decreases | metabolism "/>
<Mention id="M80" type="Trigger" span="120 9;139 15" str=" increases | bioavailability"/>
<Mention id="M81" type="Precipitant" span="85 17" str="dihydroergotamine" code="N0000005941"/>
<Interaction id="I30" type="Pharmacokinetic interaction" trigger="M79;M80" precipitant="M81" effect="C54357"/>
</Sentence>
<Sentence id="84" LabelDrug="NitroMist" section="34073-7">
<SentenceText>Patients receiving antihypertensive drugs, beta-adrenergic blockers, and nitrates should be observed for possible additive hypotensive effects.</SentenceText>
<Mention id="M90" type="Trigger" span="82 18" str="should be observed "/>
<Mention id="M91" type="Trigger" span="114 8" str=" additive"/>
<Mention id="M84" type="Precipitant" span="19 22" str="antihypertensive drugs" code="N0000029427"/>
<Mention id="M93" type="SpecificInteraction" span="123 19" str="hypotensive effects" code="45007003: Low blood pressure (disorder)"/>
<Mention id="M88" type="Precipitant" span="43 24" str="beta-adrenergic blockers" code="N0000175556"/>
<Mention id="M92" type="Precipitant" span="73 8" str="nitrates" code="N0000007647"/>
<Interaction id="I31" type="Pharmacodynamic interaction" trigger="M90;M91" precipitant="M84" effect="M93"/>
<Interaction id="I32" type="Pharmacodynamic interaction" trigger="M90;M91" precipitant="M88" effect="M93"/>
<Interaction id="I33" type="Pharmacodynamic interaction" trigger="M90;M91" precipitant="M92" effect="M93"/>
</Sentence>
<Sentence id="84" LabelDrug="NitroMist" section="34073-7">
<SentenceText>Patients receiving antihypertensive drugs, beta-adrenergic blockers, and nitrates should be observed for possible additive hypotensive effects.</SentenceText>
<Mention id="M102" type="Trigger" span="82 18" str="should be observed "/>
<Mention id="M103" type="Trigger" span="114 8" str=" additive"/>
<Mention id="M96" type="Precipitant" span="19 22" str="antihypertensive drugs" code="N0000029427"/>
<Mention id="M105" type="SpecificInteraction" span="123 19" str="hypotensive effects" code="45007003: Low blood pressure (disorder)"/>
<Mention id="M100" type="Precipitant" span="43 24" str="beta-adrenergic blockers" code="N0000175556"/>
<Mention id="M104" type="Precipitant" span="73 8" str="nitrates" code="N0000007647"/>
<Interaction id="I34" type="Pharmacodynamic interaction" trigger="M102;M103" precipitant="M96" effect="M105"/>
<Interaction id="I35" type="Pharmacodynamic interaction" trigger="M102;M103" precipitant="M100" effect="M105"/>
<Interaction id="I36" type="Pharmacodynamic interaction" trigger="M102;M103" precipitant="M104" effect="M105"/>
</Sentence>
<Sentence id="84" LabelDrug="NitroMist" section="34073-7">
<SentenceText>Patients receiving antihypertensive drugs, beta-adrenergic blockers, and nitrates should be observed for possible additive hypotensive effects.</SentenceText>
<Mention id="M114" type="Trigger" span="82 18" str="should be observed "/>
<Mention id="M115" type="Trigger" span="114 8" str=" additive"/>
<Mention id="M108" type="Precipitant" span="19 22" str="antihypertensive drugs" code="N0000029427"/>
<Mention id="M117" type="SpecificInteraction" span="123 19" str="hypotensive effects" code="45007003: Low blood pressure (disorder)"/>
<Mention id="M112" type="Precipitant" span="43 24" str="beta-adrenergic blockers" code="N0000175556"/>
<Mention id="M116" type="Precipitant" span="73 8" str="nitrates" code="N0000007647"/>
<Interaction id="I37" type="Pharmacodynamic interaction" trigger="M114;M115" precipitant="M108" effect="M117"/>
<Interaction id="I38" type="Pharmacodynamic interaction" trigger="M114;M115" precipitant="M112" effect="M117"/>
<Interaction id="I39" type="Pharmacodynamic interaction" trigger="M114;M115" precipitant="M116" effect="M117"/>
</Sentence>
<Sentence id="85" LabelDrug="NitroMist" section="34073-7">
<SentenceText>PDE5 inhibitors such as sildenafil, vardenafil, and tadalafil have been shown to potentiate the hypotensive effects of organic nitrates.</SentenceText>
<Mention id="M127" type="Trigger" span="81 10" str="potentiate"/>
<Mention id="M119" type="Precipitant" span="0 15" str="PDE5 inhibitors" code="N0000175599"/>
<Mention id="M129" type="SpecificInteraction" span="96 19" str="hypotensive effects" code="45007003: Low blood pressure (disorder)"/>
<Mention id="M122" type="Precipitant" span="24 10" str="sildenafil" code="N0000022115"/>
<Mention id="M125" type="Precipitant" span="52 9" str="tadalafil" code="N0000010536"/>
<Mention id="M128" type="Precipitant" span="36 10" str="vardenafil" code="N0000148820"/>
<Interaction id="I40" type="Pharmacodynamic interaction" trigger="M127" precipitant="M119" effect="M129"/>
<Interaction id="I41" type="Pharmacodynamic interaction" trigger="M127" precipitant="M122" effect="M129"/>
<Interaction id="I42" type="Pharmacodynamic interaction" trigger="M127" precipitant="M125" effect="M129"/>
<Interaction id="I43" type="Pharmacodynamic interaction" trigger="M127" precipitant="M128" effect="M129"/>
</Sentence>
<Sentence id="85" LabelDrug="NitroMist" section="34073-7">
<SentenceText>PDE5 inhibitors such as sildenafil, vardenafil, and tadalafil have been shown to potentiate the hypotensive effects of organic nitrates.</SentenceText>
<Mention id="M139" type="Trigger" span="81 10" str="potentiate"/>
<Mention id="M131" type="Precipitant" span="0 15" str="PDE5 inhibitors" code="N0000175599"/>
<Mention id="M141" type="SpecificInteraction" span="96 19" str="hypotensive effects" code="45007003: Low blood pressure (disorder)"/>
<Mention id="M134" type="Precipitant" span="24 10" str="sildenafil" code="N0000022115"/>
<Mention id="M137" type="Precipitant" span="52 9" str="tadalafil" code="N0000010536"/>
<Mention id="M140" type="Precipitant" span="36 10" str="vardenafil" code="N0000148820"/>
<Interaction id="I44" type="Pharmacodynamic interaction" trigger="M139" precipitant="M131" effect="M141"/>
<Interaction id="I45" type="Pharmacodynamic interaction" trigger="M139" precipitant="M134" effect="M141"/>
<Interaction id="I46" type="Pharmacodynamic interaction" trigger="M139" precipitant="M137" effect="M141"/>
<Interaction id="I47" type="Pharmacodynamic interaction" trigger="M139" precipitant="M140" effect="M141"/>
</Sentence>
<Sentence id="85" LabelDrug="NitroMist" section="34073-7">
<SentenceText>PDE5 inhibitors such as sildenafil, vardenafil, and tadalafil have been shown to potentiate the hypotensive effects of organic nitrates.</SentenceText>
<Mention id="M151" type="Trigger" span="81 10" str="potentiate"/>
<Mention id="M143" type="Precipitant" span="0 15" str="PDE5 inhibitors" code="N0000175599"/>
<Mention id="M153" type="SpecificInteraction" span="96 19" str="hypotensive effects" code="45007003: Low blood pressure (disorder)"/>
<Mention id="M146" type="Precipitant" span="24 10" str="sildenafil" code="N0000022115"/>
<Mention id="M149" type="Precipitant" span="52 9" str="tadalafil" code="N0000010536"/>
<Mention id="M152" type="Precipitant" span="36 10" str="vardenafil" code="N0000148820"/>
<Interaction id="I48" type="Pharmacodynamic interaction" trigger="M151" precipitant="M143" effect="M153"/>
<Interaction id="I49" type="Pharmacodynamic interaction" trigger="M151" precipitant="M146" effect="M153"/>
<Interaction id="I50" type="Pharmacodynamic interaction" trigger="M151" precipitant="M149" effect="M153"/>
<Interaction id="I51" type="Pharmacodynamic interaction" trigger="M151" precipitant="M152" effect="M153"/>
</Sentence>
<Sentence id="85" LabelDrug="NitroMist" section="34073-7">
<SentenceText>PDE5 inhibitors such as sildenafil, vardenafil, and tadalafil have been shown to potentiate the hypotensive effects of organic nitrates.</SentenceText>
<Mention id="M163" type="Trigger" span="81 10" str="potentiate"/>
<Mention id="M155" type="Precipitant" span="0 15" str="PDE5 inhibitors" code="N0000175599"/>
<Mention id="M165" type="SpecificInteraction" span="96 19" str="hypotensive effects" code="45007003: Low blood pressure (disorder)"/>
<Mention id="M158" type="Precipitant" span="24 10" str="sildenafil" code="N0000022115"/>
<Mention id="M161" type="Precipitant" span="52 9" str="tadalafil" code="N0000010536"/>
<Mention id="M164" type="Precipitant" span="36 10" str="vardenafil" code="N0000148820"/>
<Interaction id="I52" type="Pharmacodynamic interaction" trigger="M163" precipitant="M155" effect="M165"/>
<Interaction id="I53" type="Pharmacodynamic interaction" trigger="M163" precipitant="M158" effect="M165"/>
<Interaction id="I54" type="Pharmacodynamic interaction" trigger="M163" precipitant="M161" effect="M165"/>
<Interaction id="I55" type="Pharmacodynamic interaction" trigger="M163" precipitant="M164" effect="M165"/>
</Sentence>
<Sentence id="86" LabelDrug="NitroMist" section="34073-7">
<SentenceText>PDE5 inhibitors: Concomitant use contraindicated (4.1, 7.1) Antihypertensives: Possible additive hypotensive effects (7.2) Aspirin: increased nitroglycerin levels (7.3) Tissue-type plasminogen activator (t-PA): decreased thrombolytic effect (7.4) Heparin: anticoagulant effect of heparin may be reduced.</SentenceText>
<Mention id="M168" type="SpecificInteraction" span="88 28" str="additive hypotensive effects" code="45007003: Low blood pressure (disorder)"/>
<Mention id="M167" type="Precipitant" span="60 17" str="Antihypertensives" code="N0000178477"/>
<Mention id="M169" type="Trigger" span="132 9;156 6" str="increased | levels"/>
<Mention id="M170" type="Precipitant" span="123 7" str="Aspirin" code="N0000006582"/>
<Mention id="M171" type="Trigger" span="288 14" str="may be reduced"/>
<Mention id="M172" type="Precipitant" span="247 7" str="Heparin" code="N0000006341"/>
<Mention id="M173" type="SpecificInteraction" span="256 20;295 7" str="anticoagulant effect | reduced" code="76612001:  Hypercoagulability state (finding)"/>
<Mention id="M174" type="Trigger" span="33 15" str="contraindicated"/>
<Mention id="M175" type="Precipitant" span="0 15" str="PDE5 inhibitors" code="N0000175599"/>
<Mention id="M178" type="SpecificInteraction" span="211 29" str="decreased thrombolytic effect" code="NO MAP"/>
<Mention id="M177" type="Precipitant" span="169 40" str="Tissue-type plasminogen activator (t-PA)" code="N0000007047"/>
<Interaction id="I56" type="Pharmacodynamic interaction" trigger="M168" precipitant="M167" effect="M168"/>
<Interaction id="I57" type="Pharmacokinetic interaction" trigger="M169" precipitant="M170" effect="C54355"/>
<Interaction id="I58" type="Pharmacodynamic interaction" trigger="M171" precipitant="M172" effect="M173"/>
<Interaction id="I59" type="Unspecified interaction" trigger="M174" precipitant="M175"/>
<Interaction id="I60" type="Pharmacodynamic interaction" trigger="M178" precipitant="M177" effect="M178"/>
</Sentence>
<Sentence id="86" LabelDrug="NitroMist" section="34073-7">
<SentenceText>PDE5 inhibitors: Concomitant use contraindicated (4.1, 7.1) Antihypertensives: Possible additive hypotensive effects (7.2) Aspirin: increased nitroglycerin levels (7.3) Tissue-type plasminogen activator (t-PA): decreased thrombolytic effect (7.4) Heparin: anticoagulant effect of heparin may be reduced.</SentenceText>
<Mention id="M181" type="SpecificInteraction" span="88 28" str="additive hypotensive effects" code="45007003: Low blood pressure (disorder)"/>
<Mention id="M180" type="Precipitant" span="60 17" str="Antihypertensives" code="N0000178477"/>
<Mention id="M182" type="Trigger" span="132 9;156 6" str="increased | levels"/>
<Mention id="M183" type="Precipitant" span="123 7" str="Aspirin" code="N0000006582"/>
<Mention id="M184" type="Trigger" span="288 14" str="may be reduced"/>
<Mention id="M185" type="Precipitant" span="247 7" str="Heparin" code="N0000006341"/>
<Mention id="M186" type="SpecificInteraction" span="256 20;295 7" str="anticoagulant effect | reduced" code="76612001:  Hypercoagulability state (finding)"/>
<Mention id="M187" type="Trigger" span="33 15" str="contraindicated"/>
<Mention id="M188" type="Precipitant" span="0 15" str="PDE5 inhibitors" code="N0000175599"/>
<Mention id="M191" type="SpecificInteraction" span="211 29" str="decreased thrombolytic effect" code="NO MAP"/>
<Mention id="M190" type="Precipitant" span="169 40" str="Tissue-type plasminogen activator (t-PA)" code="N0000007047"/>
<Interaction id="I61" type="Pharmacodynamic interaction" trigger="M181" precipitant="M180" effect="M181"/>
<Interaction id="I62" type="Pharmacokinetic interaction" trigger="M182" precipitant="M183" effect="C54355"/>
<Interaction id="I63" type="Pharmacodynamic interaction" trigger="M184" precipitant="M185" effect="M186"/>
<Interaction id="I64" type="Unspecified interaction" trigger="M187" precipitant="M188"/>
<Interaction id="I65" type="Pharmacodynamic interaction" trigger="M191" precipitant="M190" effect="M191"/>
</Sentence>
<Sentence id="86" LabelDrug="NitroMist" section="34073-7">
<SentenceText>PDE5 inhibitors: Concomitant use contraindicated (4.1, 7.1) Antihypertensives: Possible additive hypotensive effects (7.2) Aspirin: increased nitroglycerin levels (7.3) Tissue-type plasminogen activator (t-PA): decreased thrombolytic effect (7.4) Heparin: anticoagulant effect of heparin may be reduced.</SentenceText>
<Mention id="M194" type="SpecificInteraction" span="88 28" str="additive hypotensive effects" code="45007003: Low blood pressure (disorder)"/>
<Mention id="M193" type="Precipitant" span="60 17" str="Antihypertensives" code="N0000178477"/>
<Mention id="M195" type="Trigger" span="132 9;156 6" str="increased | levels"/>
<Mention id="M196" type="Precipitant" span="123 7" str="Aspirin" code="N0000006582"/>
<Mention id="M197" type="Trigger" span="288 14" str="may be reduced"/>
<Mention id="M198" type="Precipitant" span="247 7" str="Heparin" code="N0000006341"/>
<Mention id="M199" type="SpecificInteraction" span="256 20;295 7" str="anticoagulant effect | reduced" code="76612001:  Hypercoagulability state (finding)"/>
<Mention id="M200" type="Trigger" span="33 15" str="contraindicated"/>
<Mention id="M201" type="Precipitant" span="0 15" str="PDE5 inhibitors" code="N0000175599"/>
<Mention id="M204" type="SpecificInteraction" span="211 29" str="decreased thrombolytic effect" code="NO MAP"/>
<Mention id="M203" type="Precipitant" span="169 40" str="Tissue-type plasminogen activator (t-PA)" code="N0000007047"/>
<Interaction id="I66" type="Pharmacodynamic interaction" trigger="M194" precipitant="M193" effect="M194"/>
<Interaction id="I67" type="Pharmacokinetic interaction" trigger="M195" precipitant="M196" effect="C54355"/>
<Interaction id="I68" type="Pharmacodynamic interaction" trigger="M197" precipitant="M198" effect="M199"/>
<Interaction id="I69" type="Unspecified interaction" trigger="M200" precipitant="M201"/>
<Interaction id="I70" type="Pharmacodynamic interaction" trigger="M204" precipitant="M203" effect="M204"/>
</Sentence>
<Sentence id="86" LabelDrug="NitroMist" section="34073-7">
<SentenceText>PDE5 inhibitors: Concomitant use contraindicated (4.1, 7.1) Antihypertensives: Possible additive hypotensive effects (7.2) Aspirin: increased nitroglycerin levels (7.3) Tissue-type plasminogen activator (t-PA): decreased thrombolytic effect (7.4) Heparin: anticoagulant effect of heparin may be reduced.</SentenceText>
<Mention id="M207" type="SpecificInteraction" span="88 28" str="additive hypotensive effects" code="45007003: Low blood pressure (disorder)"/>
<Mention id="M206" type="Precipitant" span="60 17" str="Antihypertensives" code="N0000178477"/>
<Mention id="M208" type="Trigger" span="132 9;156 6" str="increased | levels"/>
<Mention id="M209" type="Precipitant" span="123 7" str="Aspirin" code="N0000006582"/>
<Mention id="M210" type="Trigger" span="288 14" str="may be reduced"/>
<Mention id="M211" type="Precipitant" span="247 7" str="Heparin" code="N0000006341"/>
<Mention id="M212" type="SpecificInteraction" span="256 20;295 7" str="anticoagulant effect | reduced" code="76612001:  Hypercoagulability state (finding)"/>
<Mention id="M213" type="Trigger" span="33 15" str="contraindicated"/>
<Mention id="M214" type="Precipitant" span="0 15" str="PDE5 inhibitors" code="N0000175599"/>
<Mention id="M217" type="SpecificInteraction" span="211 29" str="decreased thrombolytic effect" code="NO MAP"/>
<Mention id="M216" type="Precipitant" span="169 40" str="Tissue-type plasminogen activator (t-PA)" code="N0000007047"/>
<Interaction id="I71" type="Pharmacodynamic interaction" trigger="M207" precipitant="M206" effect="M207"/>
<Interaction id="I72" type="Pharmacokinetic interaction" trigger="M208" precipitant="M209" effect="C54355"/>
<Interaction id="I73" type="Pharmacodynamic interaction" trigger="M210" precipitant="M211" effect="M212"/>
<Interaction id="I74" type="Unspecified interaction" trigger="M213" precipitant="M214"/>
<Interaction id="I75" type="Pharmacodynamic interaction" trigger="M217" precipitant="M216" effect="M217"/>
</Sentence>
<Sentence id="86" LabelDrug="NitroMist" section="34073-7">
<SentenceText>PDE5 inhibitors: Concomitant use contraindicated (4.1, 7.1) Antihypertensives: Possible additive hypotensive effects (7.2) Aspirin: increased nitroglycerin levels (7.3) Tissue-type plasminogen activator (t-PA): decreased thrombolytic effect (7.4) Heparin: anticoagulant effect of heparin may be reduced.</SentenceText>
<Mention id="M220" type="SpecificInteraction" span="88 28" str="additive hypotensive effects" code="45007003: Low blood pressure (disorder)"/>
<Mention id="M219" type="Precipitant" span="60 17" str="Antihypertensives" code="N0000178477"/>
<Mention id="M221" type="Trigger" span="132 9;156 6" str="increased | levels"/>
<Mention id="M222" type="Precipitant" span="123 7" str="Aspirin" code="N0000006582"/>
<Mention id="M223" type="Trigger" span="288 14" str="may be reduced"/>
<Mention id="M224" type="Precipitant" span="247 7" str="Heparin" code="N0000006341"/>
<Mention id="M225" type="SpecificInteraction" span="256 20;295 7" str="anticoagulant effect | reduced" code="76612001:  Hypercoagulability state (finding)"/>
<Mention id="M226" type="Trigger" span="33 15" str="contraindicated"/>
<Mention id="M227" type="Precipitant" span="0 15" str="PDE5 inhibitors" code="N0000175599"/>
<Mention id="M230" type="SpecificInteraction" span="211 29" str="decreased thrombolytic effect" code="NO MAP"/>
<Mention id="M229" type="Precipitant" span="169 40" str="Tissue-type plasminogen activator (t-PA)" code="N0000007047"/>
<Interaction id="I76" type="Pharmacodynamic interaction" trigger="M220" precipitant="M219" effect="M220"/>
<Interaction id="I77" type="Pharmacokinetic interaction" trigger="M221" precipitant="M222" effect="C54355"/>
<Interaction id="I78" type="Pharmacodynamic interaction" trigger="M223" precipitant="M224" effect="M225"/>
<Interaction id="I79" type="Unspecified interaction" trigger="M226" precipitant="M227"/>
<Interaction id="I80" type="Pharmacodynamic interaction" trigger="M230" precipitant="M229" effect="M230"/>
</Sentence>
<Sentence id="87" LabelDrug="NitroMist" section="34073-7">
<SentenceText>Plasma levels of t-PA are reduced when coadministered with nitroglycerin .</SentenceText>
<Mention id="M231" type="Trigger" span="0 13;26 7" str="Plasma levels | reduced"/>
<Mention id="M232" type="Precipitant" span="17 4" str="t-PA" code="N0000007047"/>
<Interaction id="I81" type="Pharmacokinetic interaction" trigger="M231" precipitant="M232" effect="C54358"/>
</Sentence>
<Sentence id="88" LabelDrug="NitroMist" section="34073-7">
<SentenceText>The time course and dose dependence of this interaction have not been studied, and use within a few days of one another cannot be recommended.</SentenceText>
</Sentence>
<Sentence id="89" LabelDrug="NitroMist" section="34073-7">
<SentenceText>The use of any form of nitroglycerin during the early days of acute myocardial infarction requires particular attention to hemodynamic monitoring and clinical status.</SentenceText>
</Sentence>
<Sentence id="90" LabelDrug="NitroMist" section="34073-7">
<SentenceText>The vasodilatory and hemodynamic effects of nitroglycerin may be enhanced by concomitant administration of aspirin.</SentenceText>
<Mention id="M233" type="Trigger" span="65 11" str="enhanced by"/>
<Mention id="M234" type="Precipitant" span="107 7" str="aspirin" code="N0000006582"/>
<Mention id="M235" type="SpecificInteraction" span="4 12;33 7;65 8" str="vasodilatory | effects | enhanced " code="91081006: Vasodilatation (finding)"/>
<Mention id="M236" type="SpecificInteraction" span="21 19;65 8" str=" hemodynamic effects | enhanced" code=" 422773005: Hemodynamic instability (finding)"/>
<Interaction id="I82" type="Pharmacodynamic interaction" trigger="M233" precipitant="M234" effect="M235;M236"/>
</Sentence>
<Sentence id="91" LabelDrug="NitroMist" section="34073-7">
<SentenceText>Therefore , caution should be observed in patients receiving nitroglycerin during t-PA therapy .</SentenceText>
<Mention id="M237" type="Trigger" span="12 26" str="caution should be observed"/>
<Mention id="M238" type="Precipitant" span="82 4" str="t-PA" code="N0000007047"/>
<Interaction id="I83" type="Unspecified interaction" trigger="M237" precipitant="M238"/>
</Sentence>
<Sentence id="92" LabelDrug="NitroMist" section="34073-7">
<SentenceText>Therefore , patients receiving sublingual nitroglycerin should avoid ergotamine and related drugs or be monitored for symptoms of ergotism if this is not possible .</SentenceText>
<Mention id="M239" type="Trigger" span="63 5" str="avoid "/>
<Mention id="M240" type="Trigger" span="104 9" str=" monitored"/>
<Mention id="M241" type="Precipitant" span="69 10" str="ergotamine" code="N0000006354"/>
<Mention id="M242" type="SpecificInteraction" span="118 20" str="symptoms of ergotism" code="51510002: Ergotism (disorder)"/>
<Interaction id="I84" type="Pharmacodynamic interaction" trigger="M239;M240" precipitant="M241" effect="M242"/>
</Sentence>
</Sentences>
<LabelInteractions><LabelInteraction type="Pharmacodynamic interaction" precipitant="pde5 inhibitors" precipitantCode="N0000175599" effect="45007003: Low blood pressure (disorder)"/>
<LabelInteraction type="Unspecified interaction" precipitant="pde5 inhibitors" precipitantCode="N0000175599"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="sildenafil" precipitantCode="N0000022115" effect="45007003: Low blood pressure (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="tadalafil" precipitantCode="N0000010536" effect="45007003: Low blood pressure (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="vardenafil" precipitantCode="N0000148820" effect="45007003: Low blood pressure (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="ergotamine" precipitantCode="N0000006354" effect="51510002: Ergotism (disorder)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="ergotamine" precipitantCode="N0000006354" effect="C54357"/>
<LabelInteraction type="Unspecified interaction" precipitant="selective inhibitor of cyclic guanosine monophosphate (cgmp)-specific phosphodiesterase type5 (pde5)" precipitantCode="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="heparin" precipitantCode="N0000006341" effect="76612001:  Hypercoagulability state (finding)"/>
<LabelInteraction type="Unspecified interaction" precipitant="heparin" precipitantCode="N0000006341"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="aspirin" precipitantCode="N0000006582" effect=" 422773005: Hemodynamic instability (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="aspirin" precipitantCode="N0000006582" effect="91081006: Vasodilatation (finding)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="aspirin" precipitantCode="N0000006582" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="aspirin" precipitantCode="N0000006582" effect="C54602"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="aspirin" precipitantCode="N0000006582" effect="C54605"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="labetolol" precipitantCode="N0000006446" effect="45007003: Low blood pressure (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="tissue-type plasminogen activator ( t-pa )" precipitantCode="N0000007047" effect="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="calcium channel blockers" precipitantCode="N0000029119" effect="28651003: Orthostatic hypotension (disorder)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="dihydroergotamine" precipitantCode="N0000005941" effect="C54357"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="antihypertensive drugs" precipitantCode="N0000029427" effect="45007003: Low blood pressure (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="beta-adrenergic blockers" precipitantCode="N0000175556" effect="45007003: Low blood pressure (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="nitrates" precipitantCode="N0000007647" effect="45007003: Low blood pressure (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="antihypertensives" precipitantCode="N0000178477" effect="45007003: Low blood pressure (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="tissue-type plasminogen activator (t-pa)" precipitantCode="N0000007047" effect="NO MAP"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="t-pa" precipitantCode="N0000007047" effect="C54358"/>
<LabelInteraction type="Unspecified interaction" precipitant="t-pa" precipitantCode="N0000007047"/>

</LabelInteractions></Label>